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Basal cell carcinoma (BCC) is the most common neoplasm in the Caucasian population. Only a fraction of BCC exhibits
pigmentation. Lack of melanocyte colonization has been suggested to be due to p53-inactivating mutations in the BCC cells
interfering with the p53-proopiomelanocortin pathway and the production of alpha melanocyte-stimulating hormone in the
tumor. To evaluate this, we determined tumor pigmentation as well as expression ofmelan-A and of p53 in 49 BCC tissues bymeans
of immunohistochemistry. As expected, we observed a positive relation between tumor pigmentation and melan-A positive intra-
tumoral melanocytes. Melanocyte colonization and, to a lesser extent, p53 overexpression showed intraindividual heterogeneity in
larger tumors. p53 overexpression, which is indicative of p53 mutations, was not correlated to melanocyte colonization of BCC.
Sequencing of exon 5–8 of the p53 gene in selected BCC cases revealed that colonization by melanocytes and BCC pigmentation is
neither ablated by p53 mutations nor generally present in BCCs with wild-type p53.
1. Introduction
Basal cell carcinoma (BCC) of the skin is the most common
neoplasm among the Caucasian population of the western
world [1]. It is a low-grade keratinocyte-derived neoplasm,
presents a relatively slow growth, is locally invasive and
essentially destructive, with an extremely low metastatic
potential. BCCs are commonly subdivided according to
their histological subtypes; that is, nodular, morpheaform,
micronodular, infiltrative, and superficial types that have
different disease outcome [2]. A molecular hallmark of BCC
is activation of the Hedgehog signalling pathway, involving
mutations in Patched and Smoothened [3]. Moreover, BCC
is known to be commonly associated with p53mutations [4].
A fraction of BCC tumors exhibit pigmentation even
though they are keratinocyte-derived neoplasms, due to
melanocytic colonization in the tumor, as described by
Florell et al. [5].
Concordance between p53 wild-type and melanocytic
colonization as compared to p53-mutated tumors that lacked
melanocytes in BCCs was previously described [4]. The aim
of this work was to determine melanocyte colonization in a
large number of pigmented and nonpigmented BCCs, and to
correlate this with the p53 status. Surprisingly, we did not
observe any correlation between melanocyte colonization
and p53 overexpression, which is indicative of inactivating
p53 mutations. Sequencing of exon 5-8 of 10 selected BCCs
further confirmed that melanocyte colonization of BCC is
not dependent on wild-type p53.
2. Materials andMethods
This study, analyzing human tumor samples was conducted
according to the principles expressed in the Declaration of
Helsinki. The study was approved by the Institutional Review
Board of Wu¨rzburg University Hospital. All patients pro-
vided written informed consent for the collection of samples
and subsequent analysis. Tumor material, melanin staining
and immunohistochemistry paraffin-embedded blocks of pre-
viously microscopically diagnosed BCCs of the years 2007–
2010 were analyzed. To increase the proportion of pigmented
tumors, 9 clinically pigmented BCCs were added to a series
of 40 unselected samples. Clinical data were available for all
patients.
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Four-micron sections were placed on poly-l-lysine-
coated slides. These slides were dried at 60◦C for 50
minutes followed by deparaffinization and rehydratation.
The following stainings were performed: Melanin by a mod-
ified Staemmler method [6], Melan-A (clone A103, Dako,
Denmark) [7], and p53 (Dako, Denmark) [8], all following
routine procedures and using 3-amino-9-ethylcarbazole as
chromogen.
All sections were systematically examined twice and in
part by two independent observers under high-powermagni-
fication (400×). We analyzed quantitatively the immunohis-
tochemical expression. As the positivity for melanin, melan-
A, and p53 was very heterogeneous in some tumors, we
selected three representative parts of each tumor and counted
the number of positive cells or nuclei per field. Statistical
analysis was done using the Graphpad Prism software.
Sequence Analysis of p53 Exons 5 to 8 . Five immediately
following slides from the tissue blocks were used for DNA
extraction, and adjacent slides were used to confirm the
presence of the lesion. Following deparaffinization, DNA
was extracted using a DNA isolation kit (Qiagen, Hilden,
Germany). For sequencing (SeqLab; Go¨ttingen, Germany),
the p53 exons 5, 6, 7, and 8 were amplified with Bio-
Therm Taq polymerase (GenCraft, Mu¨nster, Germany) by
seminested PCR using the following primers which all target
exon flanking intron sequences:
Exon 5-1: GTGCCCTGACTTTCAACTCTG
Exon 5-2: ATCAGTGAGGAATCAGAGGC
Exon 5-3: (nested primer) GGGCAACCAGCCCTG-
TCG
Exon 6-1: GCCTCTGATTCCTCACTGAT
Exon 6-2: GGAGGGCCACTGACAACCA
Exon 6-3: (nested primer) CCAGAGACCCCAGTT-
GCAAAC
Exon 7-1: AGGCGCACTGGCCTCATCTT
Exon 7-2: AGGGGTCAGAGGCAAGCAGA
Exon 7-3: (nested primer) TCAGAGGCAAGCAGA-
GGCTG
Exon 8-1: GGACAGGTAGGACCTGATTTCCTTAC
Exon 8-2: TGAATCTGAGGCATAACTGC
Exon 8-3: (nested primer) TGCACCCTTGGTCTC-
CTCCAC
3. Results
Sixteen out of 49 (30.6%) BCCs analyzed in this study were
clinically pigmented. The median age of the patients was
67.35 years (range 29–87 years) with a female :male ratio of
1 : 2.1. The majority (63.2%) of the BCCs were derived from
the head and neck region. The most common histological
subtype was the nodular subtype (32.6%). 8 of the 16
clinically pigmented BCCs were of this subtype (Table 1).
Surprisingly, all BCC specimens (including those lack-
ing any detectable pigmentation) harboured at least some
melan-A positive cells (Table 1). Although this might be
indicative of a small population of cells which are unspecif-
ically stained by the melan-A antibody, a highly significant
(P < .0001) correlation between the number of melan-A
positive cells and microscopic pigmentation in the melanin
staining was observed (Figure 1(a)). Melanin staining and
macroscopic pigmentation were highly concordant with the
exception of the two cases which stained positive for melanin
in the immunohistochemistry without obvious macroscopic
pigmentation (Table 1). For clinically pigmented BCC,
melanization occurred diffusely throughout the tumor nests
(Figure 2). This is in contrast to the clinically nonpigmented
BCCs, which focally showed only minimal pigmentation in
the centre of the tumor mass.
To study the relationship between melanocyte coloniza-
tion and p53 status, we analyzed p53 expression since high-
level expression of p53 expression is frequently regarded as an
indication of p53-inactivating mutations [9]. However, the
frequency of tumor cells overexpressing p53 did not correlate
with the frequency of melan-A positive cells within the
tumor mass (Figure 1(b)). Moreover, neither macroscopic
pigmentation nor melanin expression correlated with p53
expression (data not shown).
Since p53 immunohistologically detectable overexpres-
sion in cancer cells is not always caused by inactivating
mutations [9, 10], we sequenced exon 5-8 of the p53 gene in
ten selected BCC samples to confirm that the p53 expression
status is indeed a measure of p53 mutation in our BCC
tissues. For this purpose, we selected six tumor samples
displayingmacroscopic pigmentation, a relative high propor-
tion of melanin positive cells, as well as p53 overexpression
and four nonpigmented BCCs poor in melanocytes and
lacking detectable p53 expression. In the latter, we observed
only wild-type sequences for p53 (Table 1), suggesting that
the lack of melanocyte colonization in these four tumors is
indeed not due to a p53 mutation. In four pigmented BCCs,
which displayed high or intermediate positivity for p53, we
were able to detect p53 mutations (Table 1 and Figure 2). All
four mutations detected are described as missense mutations
detected in several different cancer types [11]. This confirms
that p53 overexpression can be indeed indicative for the
presence of p53 mutations in BCC specimens and even
more importantly demonstrates that the presence of p53
mutations in BCC cells is not incompatible with melanocyte
colonization. In two further pigmented BCC samples with
a high and intermediate proportion of p53 overexpressing
tumor cells, respectively, we could not detect a p53 mutation
by sequencing of exons 5-8.
4. Discussion
Pigmentation of the skin results from the synthesis of
melanin in the pigment-producing cells, the melanocytes,
followed by distribution and transport of pigment granules
to neighbouring keratinocytes [12]. Keratinocyte-derived
basal cell carcinomas display pigmentation in approxi-
mately 10% of cases in the Caucasian population [13].
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Table 1: Clinical, microscopic, immunohistologic, and sequencing data of the basal cell carcinomas analysed in this study.
Gender Localization Growth pattern Macroscopic pigmentation Melanin Melan-A p53 expression p53 sequencing
m Nose Micronodular No 0% 10% 60%
f Nose Morpheaform No 0% 7% 75%
m Forearm Nodular Yes 80% 27% 1%
m Nose Micronodular Yes 20% 15% 0%
f Lower leg Superficial No 0% 5% 90%
f Chin Superficial No 3% 3% 7%
m Cheek Nodular No 0% 15% 3%
m Temple Nodular No 0% 3% 50%
m Neck Nodular No 0% 10% 5%
m Cheek Infiltrative No 0% 10% 1%
m Nose Nodular No 0% 10% 3%
m Forehead Morpheaform No 0% 2% 3%
f Nose Nodular No 0% 15% 0%
m Breast Nodular No 0% 3% 0% wt
m Temple Superficial No 0% 7% 75%
f Periorbital Nodular No 0% 10% 0%
m Back Nodular No 0% 15% 0%
m Shoulder Superficial No 0% 7% 3%
m Neck Nodular No 0% 10% 25%
f Cheek Superficial No 0% 3% 0% wt
m Scapula Nodular Yes 15% 15% 5% g605a 202H
m Cheek Nodular Yes 10% 10% 95% g743a 248A
m Forehead Nodular No 0% 3% 3%
m Scalp Superficial Yes 7% 17% 10% wt
f Shoulder Infiltrative Yes 7% 7% 0%
m Sternum Infiltrative No 0% 2% 0%
m Sternum Micronodular No 0% 3% 60%
m Nose Infiltrative No 0% 5% 25%
f Shoulder Micronodular Yes 5% 7% 75% c844g 282G
m Forehead Micronodular No 0% 5% 45%
m Temple Morpheaform No 0% 7% 50%
f Forehead Morpheaform No 0% 3% 0%
m Cheek Micronodular No 0% 15% 0%
f Cheek Morpheaform No 0% 3% 0% wt
f Nose Micronodular No 10% 5% 0%
m Nose Micronodular No 0% 10% 0%
f Nose Morpheaform No 0% 3% 80%
m Temple Infiltrative No 0% 15% 75%
m Occipital Morpheaform No 0% 3% 0% wt
m occipital Morpheaform No 0% 3% 0%
m Arm Nodular Yes 5% 15% 7%
m Breast Nodular Yes 5% 10% 20%
f Chest Superficial Yes 7% 10% 90% c380t S127F
m Neck Nodular Yes 5% 7% 15%
f Breast Superficial Yes 5% 15% 75% wt
f Sternum Superficial Yes 5% 5% 10%
f Hip Superficial Yes 10% 10% 35%
m Forehead Superficial Yes 10% 10% 95%
m Back Superficial Yes 3% 7% 7%
m: male; f: female; Melanin, melan-A and p53 expression were assessed by immunohistochemistry; sequencing of the p53 gene was performed for the exons
4-8;
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Figure 1: Correlation of pigmentation with melanocyte colonization (a) and lack of correlation between p53 positivity and melanocyte
colonization. (b) 49 BCC tissue sections were analyzed immunohistochemically for the presence of melanin, the expression of themelanocyte
marker melan-A and p53 expression. The frequency of melanin- and p53-positive tumor cells as well as the frequency of melan-A-expressing
melanocytes was scored. (a) The correlation between melanocytes and pigmentation was statistically significant (P < .0001). (b) There was
no correlation between the frequency of melanocytes and p53 expression (P = .77).
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Melanin
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Figure 2: Melanocytic colonization in a BCC expressing mutant p53. Depicted are immunohistochemically stained tissue sections of a BCC
displaying approximately 10% melan-A positive melanocytes (a) and high levels of nuclear p53 in 90% of the tumor cells (c). The specimen
shows strong pigmentation in the centre of the lesion (b), and sequencing revealed the presence of a c380t mutation leading to an S127F
amino acid exchange (d).
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In our selected series, 30% of the lesions showedmacroscopic
pigmentation. The degree of pigmentation in the BCC
samples was related to the number of melanocytes and the
distribution of melanin in the tumor. However, the fact
that we detected melan-A positive cells also in all melanin-
negative BCCs suggests that BCC colonizing melanocytes
are not activated in the means of melanin synthesis and
transport in every case. It might be also indicative of a small
subpopulation of cells which are unspecifically stained by
the melan-A antibody. Nevertheless, the highly significant
correlation between melan-A and melanin-positive cells
suggests that the melan-A analysis is still a valid measure for
melanocyte colonization.
The tumor-suppressor protein p53 is a transcription
factor that plays an important role in the cellular response to
genotoxic stress [14]. It has been shown to directly activate
transcription of numerous genes such as those that regulate
cell-cycle progression, apoptotic pathways, and others [15].
Loss of function of p53 leads to aberrant cell growth
and survival responses and, as such, p53 dysregulation is
a major contributor in the genesis of human cancers, in
particular most skin cancers which are characterized by high
frequencies of p53 inactivating mutations [4].
Furthermore, besides such anticancerogenic activity, p53
in keratinocytes has been proposed to be the central trans-
ducer of the skin-tanning response by inducing proopiome-
lanocortin (POMC), followed by the release of the POMC
cleavage product, α melanocyte-stimulating hormone, and
subsequent recruitment and stimulation of melanocytes [4].
This, however, has been questioned by others who consider
p53 as only one important coordinator (among others) but
not as the main or sole regulator of pigmentation in the
suntan response [16]. These authors argue that melanocytes
can be stimulated via the melanocortin 1 receptor (MC1-
R) even in the absence of POMC-derived melanocortins
through other ligands, or an intrinsic, ligand independent
activity [17, 18].
One finding of Cui and colleagues supporting the central
role of keratinocytic p53 in melanocyte activation was the
tight correlation they found in 23 BCCs with only the
15 p53 wild-type tumors showing melanocyte colonization
while the 8 BCCs for which they detected p53-inactivating
mutations lacked cells expressing the melanocytic marker
MITF [4]. In our series of 49 BCC samples, we found several
examples fitting into this pattern, but overall no significant
correlation between p53 overexpression as an indication
of p53 mutation and melanocyte colonization was found
by statistical evaluation. A limitation of our (and other’s)
interpretation of data is the heterogeneity of pigmentation,
melanocyte colonization, and p53 overexpression in an
individual tumor. This was obvious in some larger nodular
BCC studied by immunohistology. Therefore, for mutation
analyses, we selected lesions with clear-cut homogeneous
expression patterns.
Sequencing of the p53-gene in 10 selected samples
demonstrated that p53 overexpression correlates with the
presence of a mutation. Most importantly, however, it
confirmed that pigmentation and melanocyte colonization
may well be present in p53 mutant BCC. Therefore, our data
support the view that p53 is unlikely to be the sole regulator
of pigmentation [16].
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